Nanoscope Therapeutics Inc.
8
1
3
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection
Role: lead
A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
Role: lead
Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
Role: lead
Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
Role: lead
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
Role: lead
Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT
Role: lead
Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease
Role: lead
Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa
Role: lead
All 8 trials loaded